<DOC>
	<DOCNO>NCT01997229</DOCNO>
	<brief_summary>The purpose study determine eculizumab safe effective treatment refractory generalize Myasthenia Gravis .</brief_summary>
	<brief_title>Safety Efficacy Eculizumab Refractory Generalized Myasthenia Gravis ( REGAIN Study )</brief_title>
	<detailed_description />
	<mesh_term>Muscle Weakness</mesh_term>
	<mesh_term>Myasthenia Gravis</mesh_term>
	<criteria>Key Male female patient ≥18 year old Diagnosis MG make follow test : 1 . Positive serologic test antiAChR Abs confirm screening , 2 . One following : 1 . History abnormal neuromuscular transmission test demonstrate singlefiber electromyography ( SFEMG ) repetitive nerve stimulation , 2 . History positive anticholinesterase test , e.g . edrophonium chloride test , 3 . Subject demonstrate improvement MG sign oral cholinesterase inhibitor , assess treat physician . MGFA Clinical Classification Class II IV screen . MGADL total score must ≥6 screen Randomization ( Day 1 ) . Subjects : 1 . Failed treatment least two immunosuppressive agent . Or , 2 . Failed treatment least one immunosuppressive agent require chronic plasma exchange IVIg Key History thymoma neoplasm thymus History thymectomy within 12 month prior screen MGFA Class I MG crisis screening ( MGFA Class V ) Use rituximab within 6 month prior screen Use IVIg PE within 4 week prior Randomization ( Day 1 )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Myasthenia Gravis</keyword>
	<keyword>Eculizumab</keyword>
	<keyword>safety</keyword>
	<keyword>efficacy</keyword>
</DOC>